ABSTRACT
Transcatheter aortic valve replacement is an effective way to treat patients with symptomatic severe aortic valve stenosis who are deemed high risk or inoperable. Current data suggest that the mortality and stroke rates are acceptable compared to surgical aortic valve replacement. There is a possible utility in moderate-risk patients as more data become available.

KEY POINTS
- In randomized trials, transcatheter aortic valve replacement (TAVR) has produced results that are comparable to surgical aortic valve replacement in high-risk patients. TAVR is superior to medical management in patients who cannot undergo surgery, although it is associated with higher rates of stroke.
- Risk assessment and suitability for TAVR is determined by a heart team composed of interventional cardiologists and cardiac surgeons. Society of Thoracic Surgeons Score and a number of other criteria mentioned below are considered during this process.
- The transfemoral arterial approach is the most common approach used by most institutions, but other approaches such as transaortic, transapical, transaxillary, and transcarotid are utilized if suitable in patients who have difficult femoral access.

Transcatheter aortic valve replacement (TAVR) has established itself as an effective way of treating high-risk patients with severe aortic valve stenosis. With new generations of existing valves and newer alternative devices, the procedure promises to become increasingly safer. The field is evolving rapidly and it will be important for interventional cardiologists and cardiac surgeons alike to stay abreast of developments. This article reviews the history of this promising procedure and examines its use in current practice.

HISTORICAL PERSPECTIVE
In 1980, Danish researcher H. R. Anderson reported developing and testing a balloon-expandable valve in animals. The technology was eventually acquired and further developed by Edwards Life Sciences (Irvine, California).

Alain Cribier started early work in humans in 2002 in France. He used a transfemoral arterial approach to approach the aortic valve transseptally, but this procedure was associated with high rates of mortality and stroke. At the same time, in the United States, animal studies were being carried out by Lars G. Svensson, Todd Dewey,
and Michael Mack to develop a transapical method of implantation,\(^4\)\(^5\) while John Webb and colleagues were also developing a transapical aortic valve implantation technique.\(^6\)^\(^7\) and later went on to develop a retrograde transfemoral technique. This latter technique became feasible once Edwards developed a catheter that could be flexed to get around the aortic arch and across the aortic valve.

As the Edwards balloon-expandable valve (Sapien) was being developed, a nitinol-based self-expandable valve system was introduced by Medtronic: the CoreValve. Following feasibility studies,\(^5\)^\(^8\) the safety and efficacy of these valves were established thorough the Placement of Aortic Transcatheter Valves (PARTNER) trial and the US CoreValve Pivotal Trial. These valves are currently approved by the US Food and Drug Administration (FDA) for patients for whom conventional surgery would pose an extreme or high risk.\(^9\)^\(^\text{11}\)

### CLINICAL TRIALS OF TAVR

The two landmark prospective randomized trials of TAVR were the PARTNER trial and CoreValve Pivotal Trial.

The PARTNER trial consisted of two parts: PARTNER A, which compared the Sapien balloon-expandable transcatheter valve with surgical aortic valve replacement in patients at high surgical risk (Society of Thoracic Surgeons [STS] score > 10%), and PARTNER B, which compared TAVR with medical therapy in patients who could not undergo surgery (combined risk of serious morbidity or death of 50% or more, and two surgeons agreeing that the patient was inoperable).

Similarly, the CoreValve Pivotal Trial compared the self-expandable transcatheter valve with conventional medical and surgical treatment.

### TAVR is comparable to surgery in outcomes, with caveats

In the PARTNER A trial, mortality rates were similar between patients who underwent Sapien TAVR and those who underwent surgical valve replacement at 30 days (3.4% and 6.5%, \(P = .07\)), 1 year (24.2% and 26.8%), and 2 years (33.9% and 35.0%). The patients in this group were randomized to either Sapien TAVR or surgery (Table 1).\(^10\)^\(^\text{12}\)

The combined rate of stroke and transient ischemic attack was higher in the patients assigned to TAVR at 30 days (5.5% with TAVR vs 2.4% with surgery, \(P = .04\)) and at 1 year (8.3% with TAVR vs 4.3% with surgery, \(P = .04\)). The difference was of small significance at 2 years (11.2% vs 6.5%, \(P = .05\)). At 30 days, the rate of major vascular complications was higher with TAVR (11.0% vs 3.2%), while surgery was associated with more frequent major bleeding episodes (19.5% vs 9.3%) and new-onset atrial fibrillation (16.0% vs 8.6%). The rate of new pacemaker requirement at 30 days was similar between the TAVR and surgical groups (3.8% vs 3.6%). Moderate or severe paravalvular aortic regurgitation was more common after TAVR at 30 days, 1 year, and 2 years. This aortic insufficiency was associated with increased late mortality.\(^\text{10}\)^\(^\text{12}\)

In the US CoreValve High Risk Study, no difference was found in the 30-day mortality rate in patients at high surgical risk randomized to CoreValve TAVR or surgery (3.3% and 4.5%) (Table 1). Surprisingly, the 1-year mortality rate was lower in the TAVR group than in the surgical group (14.1% vs 18.9%, respectively), a finding sustained at 2 years in data presented at the American College of Cardiology conference in March 2015.\(^\text{13}\)^\(^\text{16}\)

TAVR is superior to medical management, but the risk of stroke is higher

In the PARTNER B trial, inoperable patients were randomly assigned to undergo TAVR with a Sapien valve or medical management. TAVR resulted in lower mortality rates at 1 year (30.7% vs 50.7%) and 2 years (43.4% vs 68.0%) compared with medical management (Table 1).\(^17\) Of note, medical management included balloon valvuloplasty. The rate of the composite end point of death or repeat hospitalization was also lower with TAVR compared with medical therapy (44.1% vs 71.6%, respectively, at 1 year and 56.7% and 87.9%, respectively, at 2 years).\(^17\) The TAVR group had a higher stroke rate than the medical therapy group at 30 days (11.2% vs 5.5%, respectively) and at 2 years (13.8% vs 5.5%).\(^17\) Survival improved with TAVR in patients with an STS score of less than 15% but not in those with an STS score of 15% or higher.\(^9\)

The very favorable results from the PARTNER trial rendered a randomized trial comparing self-expanding (CoreValve) TAVR and medical therapy unethical. Instead, a prospective single-arm study, the CoreValve Extreme Risk US Pivotal Trial, was used to compare the 12-month rate of death or major stroke with CoreValve TAVR vs a prespecified estimate of this rate with medical therapy.\(^14\) In about 500 patients who had a CoreValve attempt, the rate of all-cause mortality or major stroke at 1 year was significantly lower than the prespecified ex-
TRANSCATHETER AORTIC VALVE REPLACEMENT

Table 1. TAVR compared with surgery or medical therapy: results from three studies

<table>
<thead>
<tr>
<th></th>
<th>TAVR</th>
<th>Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARTNER A trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality, 30 days</td>
<td>3.4%</td>
<td>6.5%</td>
</tr>
<tr>
<td>Mortality, 1 year</td>
<td>24.3%</td>
<td>26.8%</td>
</tr>
<tr>
<td>Mortality, 2 years</td>
<td>33.9%</td>
<td>35.0%</td>
</tr>
<tr>
<td>Stroke or TIA, 30 days</td>
<td>5.5% *</td>
<td>2.4% *</td>
</tr>
<tr>
<td>Stroke or TIA, 1 year</td>
<td>8.7%</td>
<td>4.3% *</td>
</tr>
<tr>
<td>Stroke or TIA, 2 years</td>
<td>11.2%</td>
<td>6.5% *</td>
</tr>
<tr>
<td>Major vascular complications</td>
<td>11.0%</td>
<td>3.2% *</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>9.3%</td>
<td>19.5% *</td>
</tr>
<tr>
<td>New atrial fibrillation</td>
<td>8.6%</td>
<td>16.0% *</td>
</tr>
<tr>
<td>New pacemaker</td>
<td>3.8%</td>
<td>3.6%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>TAVR</th>
<th>Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>US CoreValve High Risk Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality, 30 days</td>
<td>22.2%</td>
<td>28.6%</td>
</tr>
<tr>
<td>Mortality, 1 year</td>
<td>14.1%</td>
<td>18.9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>TAVR</th>
<th>Medical therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARTNER B trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality, 1 year</td>
<td>30.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Mortality, 2 years</td>
<td>43.4%</td>
<td>68%</td>
</tr>
<tr>
<td>Death or repeat hospitalization</td>
<td>42.5%</td>
<td>71.6%</td>
</tr>
<tr>
<td>Stroke, 30 days</td>
<td>6.7%</td>
<td>1.7%</td>
</tr>
<tr>
<td>Stroke, 2 years</td>
<td>13.8%</td>
<td>5.5%</td>
</tr>
</tbody>
</table>

*Statistically significant.

TAVR = transcatheter aortic valve replacement; TIA = transient ischemic attack.

expected rate (26% vs 43%), reinforcing the results from the PARTNER Trial.14

Five-year outcomes

The 5-year PARTNER clinical and valve performance outcomes were published recently18 and continued to demonstrate equivalent outcomes for high-risk patients who underwent surgical aortic valve replacement or TAVR; there were no significant differences in all-cause mortality, cardiovascular mortality, stroke, or need for readmission to the hospital. The functional outcomes were similar as well, and no differences were demonstrated between surgical and TAVR valve performance.

Of note, moderate or severe aortic regurgitation occurred in 14% of patients in the TAVR group compared with 1% in the surgical aortic valve replacement group ($P < .0001$). This was associated with increased 5-year risk of death in the TAVR group (72.4% in those with moderate or severe aortic regurgitation vs 56.6% in those with mild aortic regurgitation or less; $P = .003$).

If the available randomized data are combined with observational reports, overall mortality and stroke rates are comparable between surgical aortic valve replacement and balloon-expandable or self-expandable TAVR in high-risk surgical candidates. Vascular complications, aortic regurgitation and permanent pacemaker insertion occur more frequently after TAVR, while major bleeding is more likely to occur after surgery.19 As newer generations of valves are developed, it is expected that aortic regurgitation and pacemaker rates will decrease over time. Indeed, trial data presented at the American College of Cardiology meeting in March 2015 for the third-generation Sapien valve (Sapien S3) showed only a 3.0% to 4.2% rate of significant paravalvular leak.

Contemporary valve comparison data

The valve used in the original PARTNER data was the first-generation Sapien valve. Since then, the second generation of this valve, the Sapien XT, has been introduced and is the model currently used in the United States (with the third-genera- tion valve mentioned above, the Sapien S3, still available only through clinical trials). Thus, the two contemporary valves available for commercial use in the United States are the Edwards Sapien XT and Medtronic CoreValve. There are limited data comparing these valves head-to-head, but one recent trial attempted to do just that.

The Comparison of Transcatheter Heart Valves in High Risk Patients with Severe Aortic Stenosis: Medtronic CoreValve vs Edwards Sapien XT (CHOICE) trial compared the Edwards Sapien XT and CoreValve devices. Two hundred and forty-one patients were randomized. The primary end point of this trial was “device success” (a composite end point of four components: successful vascular access and deployment of the device with retrieval of the delivery system, correct position of the device, intended performance of the valve without moderate or severe insufficiency, and only one valve implanted in the correct anatomical location).

In this trial, the balloon-expandable Sapien XT valve showed a significantly higher device success rate than the
the back of sternum), severely compromised respiratory function (forced expiratory volume in 1 second <1 L or <40% predicted, diffusing capacity for carbon monoxide <30%), severe pulmonary hypertension, severe liver disease (Model for End-stage Liver Disease score 8–20), severe dementia, severe cerebrovascular disease, and frailty.

With regard to this last risk factor, frailty is not simply old age but rather a measurable characteristic akin to weakness or disability. Several tests exist to measure frailty, including the “eyeball test” (the physician’s subjective assessment), Mini-Mental State Examination, gait speed/15-foot walk test, hand grip strength, serum albumin, and assessment of activities of daily living. Formal frailty testing is recommended during the course of a TAVR workup.

Risk assessment and patient suitability for TAVR is ultimately determined by the combined judgment of the heart valve team using both the STS score and consideration of these other factors.

Implantation approaches

Today, TAVR could be performed by several approaches: transfemoral arterial, transapical, transaortic via partial sternotomy or right anterior thoracotomy,21,22 transcarotid,23–25 and transaxillary or subclavian.26,27 Less commonly, transfemoral-venous routes have been performed utilizing either transseptal28 or caval-aortic puncture.29

The transfemoral approach is used most commonly by most institutions, including Cleveland Clinic. It allows for a completely percutaneous insertion and, in select cases, without endotracheal intubation and general anesthesia (Figure 1).
In patients with difficult femoral access due to severe calcification, extreme tortuosity, or small diameter, alternative access routes become a consideration. In this situation, at our institution, we favor the transapical approach in patients who have not undergone cardiac surgery in the past, while the transapical approach is used in patients who had previous cardiac surgery. With the transapical approach, we have found the outcomes similar to those of transfemoral TAVR after propensity matching. Although there is a learning curve, transapical TAVR can be performed with very limited morbidity and mortality. In a recent series at Cleveland Clinic, the mortality rate with the transapical approach was 1.2%, renal failure occurred in 4.7%, and a pacemaker was placed in 5.9% of patients; there were no strokes. This approach can be utilized for simultaneous additional procedures like transcatheter mitral valve reimplantation and percutaneous coronary interventions.

CORRESPONDENCE:
Ahmad Zeeshan, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue, J-133, Cleveland, OH 44195; e-mail: zeeshad@ccf.org

REFERENCES

doi: 10.3949/ccjm.82.s2.02